Cargando…

Development of OX40 agonists for canine cancer immunotherapy

Recent breakthroughs in cancer immunotherapy have provided unprecedented clinical benefits to human cancer patients. Cancer is also one of the most common causes of death in pet dogs. Thus, canine-specific immune therapies targeting similar signaling pathways can provide better treatment options for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruiz, Damien, Haynes, Chloe, Marable, Jonathan, Pundkar, Chetan, Nance, Rebecca L., Bedi, Deepa, Agarwal, Payal, Suryawanshi, Amol S., Mishra, Amarjit, Smith, Bruce F., Sandey, Maninder
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547195/ https://www.ncbi.nlm.nih.gov/pubmed/36217551 http://dx.doi.org/10.1016/j.isci.2022.105158

Ejemplares similares

Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
por: Marable, Jonathan, et al.
Publicado: (2021)

Characterization of Canine Adenovirus Type 2 Virus Infection Pattern in Canine and Human Cell Lines
por: Hogans, Madison D., et al.
Publicado: (2022)

Dimethyl fumarate abrogates dust mite‐induced allergic asthma by altering dendritic cell function
por: Jaiswal, Anil K., et al.
Publicado: (2019)

Short palate, lung, and nasal epithelial clone 1 (SPLUNC1) level determines steroid-resistant airway inflammation in aging
por: Jaiswal, Anil Kumar, et al.
Publicado: (2022)

Irg1/itaconate metabolic pathway is a crucial determinant of dendritic cells immune-priming function and contributes to resolute allergen-induced airway inflammation
por: Jaiswal, Anil Kumar, et al.
Publicado: (2021)

Targeting Wnt/β-catenin signaling using XAV939 nanoparticles in tumor microenvironment-conditioned macrophages promote immunogenicity
por: Pundkar, Chetan, et al.
Publicado: (2023)

Analysis of endogenous and exogenous tumor upregulated promoter expression in canine tumors
por: Sajib, Abdul Mohin, et al.
Publicado: (2020)

Cell-Surface Integrins and CAR Are Both Essential for Adenovirus Type 5 Transduction of Canine Cells of Lymphocytic Origin
por: Agarwal, Payal, et al.
Publicado: (2017)

Dendritic Cell-Restricted Progenitors Contribute to Obesity-Associated Airway Inflammation via Adam17-p38 MAPK-Dependent Pathway
por: Jaiswal, Anil Kumar, et al.
Publicado: (2020)

Transcriptomic Analysis of Canine Osteosarcoma from a Precision Medicine Perspective Reveals Limitations of Differential Gene Expression Studies
por: Nance, Rebecca L., et al.
Publicado: (2022)

Single-Nuclei Multiome (ATAC + Gene Expression) Sequencing of a Primary Canine Osteosarcoma Elucidates Intra-Tumoral Heterogeneity and Characterizes the Tumor Microenvironment
por: Nance, Rebecca L., et al.
Publicado: (2023)

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
por: Linch, Stefanie N., et al.
Publicado: (2015)

Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination
por: Chu, Yanhong, et al.
Publicado: (2021)

Structural Basis of a Novel Agonistic Anti-OX40 Antibody
por: Zhang, Jing, et al.
Publicado: (2022)

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

Evaluation of tumor immunity after administration of conditionally replicative adenoviral vector in canine osteosarcoma patients
por: Agarwal, Payal, et al.
Publicado: (2021)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist
por: Pieper, Alexander A., et al.
Publicado: (2023)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
por: Fromm, George, et al.
Publicado: (2018)

Differential Expression of miRNAs in Hypoxia (“HypoxamiRs”) in Three Canine High-Grade Glioma Cell Lines
por: Koehler, Jennifer, et al.
Publicado: (2020)

Airway Wall Expression of OX40/OX40L and Interleukin-4 in Asthma
por: Siddiqui, Salman, et al.
Publicado: (2010)

Expression of gp34 (OX40 Ligand) and OX40 on Human T Cell Clones
por: Takasawa, Naruhiko, et al.
Publicado: (2001)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
por: Cui, Dawei, et al.
Publicado: (2019)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Phage Ligands for Identification of Mesenchymal-Like Breast Cancer Cells and Cancer-Associated Fibroblasts
por: Jones, Kelvin M., et al.
Publicado: (2018)

OX40L-OX40 Interactions: A Possible Target for Gastrointestinal Autoimmune Diseases
por: Mahmood, Tahrin, et al.
Publicado: (2012)

Crucial role of OX40/OX40L signaling in a murine model of asthma
por: Lei, Wei, et al.
Publicado: (2018)

Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis
por: Zhou, Xiaoling, et al.
Publicado: (2022)

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
por: Lé, Ana Maria, et al.
Publicado: (2022)

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization
por: Zhang, Di, et al.
Publicado: (2017)

OX40/OX40L in systemic lupus erythematosus: Association with disease activity and lupus nephritis
por: Farres, Mohamed N., et al.
Publicado: (2011)

The OX40/OX40L Axis Regulates T Follicular Helper Cell Differentiation: Implications for Autoimmune Diseases
por: Fu, NanNan, et al.
Publicado: (2021)

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
por: Kim, Tae Won, et al.
Publicado: (2022)

Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy
por: Sun, Zhichen, et al.
Publicado: (2023)

Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy
por: Fromm, George, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kqarqh32fi53v5prqlp32dn397